RxDoctor Payments Data

Brittany Griffin

Family · Statesville, NCNPI 1508641440

Payments from drug & device makers

$6,185in general payments, 2019–2025

Across 273 payments — averaging $22.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$529
  • Pfizer$431
  • Lilly USA, LLC$424
  • Amgen$387
  • AbbVie$373
  • plus $3K from 28 others

What the payments were for

  • Food & beverage$6,185100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,185 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$93,515
Medicare patients
242
Services billed
4,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide110$123,826
OzempicSemaglutide110$123,469
VraylarCariprazine Hcl44$67,126
JardianceEmpagliflozin43$47,709
MyrbetriqMirabegron27$21,967
LinzessLinaclotide25$20,319
FarxigaDapagliflozin Propanediol25$20,106
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,694
Repatha SureclickEvolocumab19$12,604
VascepaIcosapent Ethyl17$9,638
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen326$8,112
VeozahFezolinetant11$7,807
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen156$5,039
Ventolin HfaAlbuterol Sulfate15$2,321
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$424$123,826110 claims
Novo NordiskOzempic$529$123,469110 claims
AbbVieVraylar, Linzess$373$87,44569 claims
Boehringer IngelheimJardiance$207$47,70943 claims
Astellas Pharma US IncMyrbetriq, Veozah$113$29,77538 claims
AstraZenecaFarxiga$1,191$20,10625 claims
GSKTrelegy Ellipta$146$15,69424 claims
PfizerPaxlovid$431$1,42932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Statesville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →